首页 > 最新文献

Journal of psychiatric research最新文献

英文 中文
Mindfulness-based group therapy for auditory hallucination management in schizophrenia: A randomized controlled trial 以正念为基础的团体治疗精神分裂症的幻听管理:一项随机对照试验
IF 3.2 2区 医学 Q1 PSYCHIATRY Pub Date : 2026-02-11 DOI: 10.1016/j.jpsychires.2026.02.019
Shuixian Yang , Wenqing Zhou , Yingying Qin , Tao Zheng , Fengxia Huang , Chunqun Li , Jingxin Dai , Lina Zhou , Linmin Li , Fengchun Wu , Qiubi Tang
Auditory hallucinations, a core symptom of schizophrenia, affect 50-70% of patients and significantly impair their quality of life. Although multimodal treatments, including pharmacotherapy, psychotherapy, and neuromodulation, are commonly employed, their efficacy remains limited. This randomized controlled trial aimed to assess the effects of Mindfulness-Based Auditory Hallucination Management (MBAHM) on auditory hallucinations, anxiety, depression, and quality of life in patients with schizophrenia. Eighty patients with schizophrenia were randomly assigned to the MBAHM group (n = 40) or the control group (n = 40). The MBAHM group received a 2-h MBAHM intervention twice a week for eight weeks, while the control group received routine treatment and care. Auditory hallucinations, anxiety, depression, and quality of life were assessed at baseline and post-intervention. The results revealed that, compared to both the baseline and the control group, the MBAHM group showed significant reductions in auditory hallucinations, anxiety, and depression, along with improvements in quality of life (p < 0.001). Correlation analyses further indicated significant associations between reductions in auditory hallucination severity, anxiety, and depression, alongside improvements in quality of life. These findings provide preliminary evidence that MBAHM may be an effective complementary approach for managing auditory hallucinations and improving overall well-being in patients with schizophrenia.

Trial registration

Chinese Clinical Trial Registry ChiCTR2400088029. Date of registration: August 09, 2024.
幻听是精神分裂症的核心症状,影响了50-70%的患者,严重损害了他们的生活质量。虽然多模式治疗,包括药物治疗、心理治疗和神经调节,通常被采用,但其疗效仍然有限。本随机对照试验旨在评估基于正念的幻听管理(MBAHM)对精神分裂症患者幻听、焦虑、抑郁和生活质量的影响。80例精神分裂症患者随机分为MBAHM组(n = 40)和对照组(n = 40)。MBAHM组给予每周一次2小时的MBAHM干预,持续8周,对照组给予常规治疗和护理。在基线和干预后评估幻听、焦虑、抑郁和生活质量。结果显示,与基线组和对照组相比,MBAHM组在幻听、焦虑和抑郁方面显著减少,生活质量也有所改善(p < 0.001)。相关分析进一步表明,幻听严重程度、焦虑和抑郁程度的降低与生活质量的改善之间存在显著关联。这些发现提供了初步证据,表明MBAHM可能是一种有效的补充方法,用于治疗幻听和改善精神分裂症患者的整体健康状况。中国临床试验注册中心ChiCTR2400088029。注册日期:2024年8月9日。
{"title":"Mindfulness-based group therapy for auditory hallucination management in schizophrenia: A randomized controlled trial","authors":"Shuixian Yang ,&nbsp;Wenqing Zhou ,&nbsp;Yingying Qin ,&nbsp;Tao Zheng ,&nbsp;Fengxia Huang ,&nbsp;Chunqun Li ,&nbsp;Jingxin Dai ,&nbsp;Lina Zhou ,&nbsp;Linmin Li ,&nbsp;Fengchun Wu ,&nbsp;Qiubi Tang","doi":"10.1016/j.jpsychires.2026.02.019","DOIUrl":"10.1016/j.jpsychires.2026.02.019","url":null,"abstract":"<div><div>Auditory hallucinations, a core symptom of schizophrenia, affect 50-70% of patients and significantly impair their quality of life. Although multimodal treatments, including pharmacotherapy, psychotherapy, and neuromodulation, are commonly employed, their efficacy remains limited. This randomized controlled trial aimed to assess the effects of Mindfulness-Based Auditory Hallucination Management (MBAHM) on auditory hallucinations, anxiety, depression, and quality of life in patients with schizophrenia. Eighty patients with schizophrenia were randomly assigned to the MBAHM group (n = 40) or the control group (n = 40). The MBAHM group received a 2-h MBAHM intervention twice a week for eight weeks, while the control group received routine treatment and care. Auditory hallucinations, anxiety, depression, and quality of life were assessed at baseline and post-intervention. The results revealed that, compared to both the baseline and the control group, the MBAHM group showed significant reductions in auditory hallucinations, anxiety, and depression, along with improvements in quality of life (p &lt; 0.001). Correlation analyses further indicated significant associations between reductions in auditory hallucination severity, anxiety, and depression, alongside improvements in quality of life. These findings provide preliminary evidence that MBAHM may be an effective complementary approach for managing auditory hallucinations and improving overall well-being in patients with schizophrenia.</div></div><div><h3>Trial registration</h3><div>Chinese Clinical Trial Registry ChiCTR2400088029. Date of registration: August 09, 2024.</div></div>","PeriodicalId":16868,"journal":{"name":"Journal of psychiatric research","volume":"196 ","pages":"Pages 53-60"},"PeriodicalIF":3.2,"publicationDate":"2026-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146172395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association between handgrip strength and incident depression: a meta-analysis of prospective cohort studies 握力与抑郁症的关系:前瞻性队列研究的荟萃分析
IF 3.2 2区 医学 Q1 PSYCHIATRY Pub Date : 2026-02-11 DOI: 10.1016/j.jpsychires.2026.02.023
Jênifer de Oliveira , Ismael Mignoni , Davy Vancampfort , Liye Zou , Brendon Stubbs , Aline Josiane Waclawovsky , Felipe Barreto Schuch
A number of individual studies have suggested that higher handgrip strength is associated with a lower risk of depressive symptoms but the totality of the evidence remains inconclusive. This study aimed to investigate the association between handgrip strength and the incidence of depressive symptoms or depression and explore potential moderators of this association. We searched major databases (PubMed, Web of Science, PsycINFO, EMBASE, and SportDiscus) from inception to February 4, 2025, for prospective cohort studies evaluating the risk of incident depressive outcomes according to handgrip strength. Effect sizes extracted were the most adjusted model containing odds ratios (ORs) or relative risks (RRs) from individual studies. Random-effects meta-analyses were conducted for ORs and RRs separately, and potential moderators were explored through meta-regressions (% women, sample size, % smokers, age, number of adjustment variables, follow-up time, and person-years). Methodological quality was assessed using the Newcastle–Ottawa Scale. Twelve unique cohorts were included (N = 497,336, person-years = 3,442,910). Individuals with lower handgrip strength had higher odds of incident depressive outcomes (OR = 1.42, 95% CI = 1.14–1.78, p < 0.001). Follow-up time (β = 0.0089, 95% CI = 0.0082–0.0096, R2 = 1.00) and person-years (β = 0.00000057, 95% CI = 0.00000028–0.00000086, R2 = 0.91) were identified as statistically significant moderators of this association, with studies showing slightly stronger associations, although the magnitude of these effects was small. The average methodological quality score of the studies was 8 (SD = 0.63), indicating overall high quality. This meta-analysis demonstrates a statistically significant but clinically small association between handgrip strength and the incidence of depressive outcomes. These findings suggest that handgrip strength may represent a convenient marker of overall health and functional resilience associated with depression risk.
许多个人研究表明,握力越强,抑郁症状的风险越低,但总体证据仍不确定。本研究旨在探讨握力与抑郁症状或抑郁发生率之间的关系,并探讨这种关系的潜在调节因子。我们检索了主要数据库(PubMed, Web of Science, PsycINFO, EMBASE和SportDiscus),从成立到2025年2月4日,根据握力评估事件抑郁结果风险的前瞻性队列研究。提取的效应量是包含个别研究的优势比(ORs)或相对风险(rr)的调整程度最高的模型。分别对ORs和rr进行随机效应荟萃分析,并通过荟萃回归(女性百分比、样本量、吸烟者百分比、年龄、调整变量数量、随访时间和人年)探索潜在的调节因素。采用纽卡斯尔-渥太华量表评估方法学质量。纳入了12个独特的队列(N = 497,336,人年= 3,442,910)。握力较低的个体发生抑郁结局的几率较高(OR = 1.42, 95% CI = 1.14-1.78, p < 0.001)。随访时间(β = 0.0089, 95% CI = 0.0082-0.0096, R2 = 1.00)和人年(β = 0.00000057, 95% CI = 0.00000028-0.00000086, R2 = 0.91)被确定为具有统计学意义的调节因素,尽管这些影响的幅度很小,但研究显示相关性略强。研究的平均方法学质量评分为8分(SD = 0.63),总体质量较高。这项荟萃分析显示,握力与抑郁结局发生率之间存在统计学上显著但临床上较小的关联。这些发现表明,握力可能是与抑郁风险相关的整体健康和功能恢复力的一个方便标志。
{"title":"Association between handgrip strength and incident depression: a meta-analysis of prospective cohort studies","authors":"Jênifer de Oliveira ,&nbsp;Ismael Mignoni ,&nbsp;Davy Vancampfort ,&nbsp;Liye Zou ,&nbsp;Brendon Stubbs ,&nbsp;Aline Josiane Waclawovsky ,&nbsp;Felipe Barreto Schuch","doi":"10.1016/j.jpsychires.2026.02.023","DOIUrl":"10.1016/j.jpsychires.2026.02.023","url":null,"abstract":"<div><div>A number of individual studies have suggested that higher handgrip strength is associated with a lower risk of depressive symptoms but the totality of the evidence remains inconclusive. This study aimed to investigate the association between handgrip strength and the incidence of depressive symptoms or depression and explore potential moderators of this association. We searched major databases (PubMed, Web of Science, PsycINFO, EMBASE, and SportDiscus) from inception to February 4, 2025, for prospective cohort studies evaluating the risk of incident depressive outcomes according to handgrip strength. Effect sizes extracted were the most adjusted model containing odds ratios (ORs) or relative risks (RRs) from individual studies. Random-effects meta-analyses were conducted for ORs and RRs separately, and potential moderators were explored through meta-regressions (% women, sample size, % smokers, age, number of adjustment variables, follow-up time, and person-years). Methodological quality was assessed using the Newcastle–Ottawa Scale. Twelve unique cohorts were included (N = 497,336, person-years = 3,442,910). Individuals with lower handgrip strength had higher odds of incident depressive outcomes (OR = 1.42, 95% CI = 1.14–1.78, p &lt; 0.001). Follow-up time (β = 0.0089, 95% CI = 0.0082–0.0096, R<sup>2</sup> = 1.00) and person-years (β = 0.00000057, 95% CI = 0.00000028–0.00000086, R<sup>2</sup> = 0.91) were identified as statistically significant moderators of this association, with studies showing slightly stronger associations, although the magnitude of these effects was small. The average methodological quality score of the studies was 8 (SD = 0.63), indicating overall high quality. This meta-analysis demonstrates a statistically significant but clinically small association between handgrip strength and the incidence of depressive outcomes. These findings suggest that handgrip strength may represent a convenient marker of overall health and functional resilience associated with depression risk.</div></div>","PeriodicalId":16868,"journal":{"name":"Journal of psychiatric research","volume":"196 ","pages":"Pages 106-114"},"PeriodicalIF":3.2,"publicationDate":"2026-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146172316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effectiveness of digitally-delivered interventions for trichotillomania and skin picking disorder: A systematic review and meta-analysis. 对拔毛癖和抠皮障碍的数字化干预的有效性:系统回顾和荟萃分析。
IF 3.2 2区 医学 Q1 PSYCHIATRY Pub Date : 2026-02-11 DOI: 10.1016/j.jpsychires.2026.02.020
Kathryn E Barber, Isabella F Cram, Elyse C Smith, Douglas W Woods, Han Joo Lee

Trichotillomania (TTM) and excoriation disorder (skin picking) disorder (SPD) are common yet undertreated conditions. Although evidence-based cognitive behavioral treatments exist, therapy access is often limited by insufficient provider availability, cost, and stigma. Several technology-based interventions have emerged as a scalable and accessible alternative, but their overall effectiveness for TTM and SPD remains unclear. This systematic review and meta-analysis evaluated the efficacy of digitally-delivered interventions for TTM and SPD. The review protocol was pre-registered on PROSPERO. PsycINFO, MEDLINE, and Embase were searched for studies testing digital interventions for TTM/SPD grounded in cognitive and/or behavioral therapies, including both therapist-assisted and self-guided formats and both controlled and uncontrolled study designs. Random-effects meta-analyses estimated within-group effect sizes for all included studies and between-group effects for randomized controlled trials. Subgroup analyses examined study, sample, and intervention characteristics. Fourteen studies (N = 5468) met inclusion criteria. Large within-group effect sizes were found for symptom reduction from pre- to post-treatment (g = 1.01), with sustained follow-up effects (1-3 months: g = 1.22; 6 months: g = 1.15). Between-group analyses of randomized controlled trials showed a medium effect favoring digital interventions over control (g = 0.63). Subgroup analyses showed trends toward stronger effects in interventions that explicitly incorporated ACT-based therapeutic content and included accountability features (e.g., reminders, therapist messaging). Effects for secondary outcomes (quality of life, depression, anxiety) were minimal. Overall, digitally-delivered interventions are associated with meaningful reductions in TTM and SPD symptom severity. Although heterogeneity and variability in study design warrant cautious interpretation, these findings support digital interventions as a promising option for improving access to care.

拔毛癖(TTM)和刮伤障碍(抠皮)障碍(SPD)是常见但治疗不足的疾病。尽管存在基于证据的认知行为治疗,但治疗的可及性往往受到提供者可用性不足、费用和耻辱感的限制。一些基于技术的干预措施已经成为可扩展和可获得的替代方案,但它们对TTM和SPD的总体有效性仍不清楚。本系统综述和荟萃分析评估了数字化提供的TTM和SPD干预措施的有效性。审查方案已在PROSPERO上预先注册。我们检索了PsycINFO、MEDLINE和Embase,以测试基于认知和/或行为疗法的TTM/SPD的数字干预,包括治疗师辅助和自我指导格式,以及受控和非受控研究设计。随机效应荟萃分析估计了所有纳入研究的组内效应大小和随机对照试验的组间效应大小。亚组分析检查了研究、样本和干预特征。14项研究(N = 5468)符合纳入标准。治疗前后症状减轻的组内效应较大(g = 1.01),随访效果持续(1-3个月:g = 1.22; 6个月:g = 1.15)。随机对照试验的组间分析显示,数字干预比对照有中等效应(g = 0.63)。亚组分析显示,明确纳入基于act的治疗内容并包含问责特征(例如,提醒、治疗师信息传递)的干预措施有更强效果的趋势。次要结果(生活质量、抑郁、焦虑)的影响很小。总体而言,数字化干预与TTM和SPD症状严重程度的显著降低有关。尽管研究设计的异质性和可变性需要谨慎解释,但这些发现支持数字干预作为改善护理可及性的有希望的选择。
{"title":"Effectiveness of digitally-delivered interventions for trichotillomania and skin picking disorder: A systematic review and meta-analysis.","authors":"Kathryn E Barber, Isabella F Cram, Elyse C Smith, Douglas W Woods, Han Joo Lee","doi":"10.1016/j.jpsychires.2026.02.020","DOIUrl":"https://doi.org/10.1016/j.jpsychires.2026.02.020","url":null,"abstract":"<p><p>Trichotillomania (TTM) and excoriation disorder (skin picking) disorder (SPD) are common yet undertreated conditions. Although evidence-based cognitive behavioral treatments exist, therapy access is often limited by insufficient provider availability, cost, and stigma. Several technology-based interventions have emerged as a scalable and accessible alternative, but their overall effectiveness for TTM and SPD remains unclear. This systematic review and meta-analysis evaluated the efficacy of digitally-delivered interventions for TTM and SPD. The review protocol was pre-registered on PROSPERO. PsycINFO, MEDLINE, and Embase were searched for studies testing digital interventions for TTM/SPD grounded in cognitive and/or behavioral therapies, including both therapist-assisted and self-guided formats and both controlled and uncontrolled study designs. Random-effects meta-analyses estimated within-group effect sizes for all included studies and between-group effects for randomized controlled trials. Subgroup analyses examined study, sample, and intervention characteristics. Fourteen studies (N = 5468) met inclusion criteria. Large within-group effect sizes were found for symptom reduction from pre- to post-treatment (g = 1.01), with sustained follow-up effects (1-3 months: g = 1.22; 6 months: g = 1.15). Between-group analyses of randomized controlled trials showed a medium effect favoring digital interventions over control (g = 0.63). Subgroup analyses showed trends toward stronger effects in interventions that explicitly incorporated ACT-based therapeutic content and included accountability features (e.g., reminders, therapist messaging). Effects for secondary outcomes (quality of life, depression, anxiety) were minimal. Overall, digitally-delivered interventions are associated with meaningful reductions in TTM and SPD symptom severity. Although heterogeneity and variability in study design warrant cautious interpretation, these findings support digital interventions as a promising option for improving access to care.</p>","PeriodicalId":16868,"journal":{"name":"Journal of psychiatric research","volume":"196 ","pages":"244-256"},"PeriodicalIF":3.2,"publicationDate":"2026-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146227283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Frequency-dependent brain state dynamic alterations in autism spectrum disorder: A co-activation pattern analysis. 自闭症谱系障碍中频率依赖的脑状态动态改变:一种共同激活模式分析。
IF 3.2 2区 医学 Q1 PSYCHIATRY Pub Date : 2026-02-10 DOI: 10.1016/j.jpsychires.2026.02.006
Simeng An, Liming Fan, Yutong Wu, Xing Su, Qian Zhu, Nan Yao, Chunwang Su, Zi-Gang Huang, Youjun Li

Autism spectrum disorder (ASD) is a complex neurodevelopmental disorder that affects normal brain development and results in impaired brain function. Most studies have focused on connectivity changes within the traditional low-frequency range, whereas the frequency-dependent nature of brain dynamics remains largely unexplored. This study employed whole-brain co-activation pattern (CAP) analysis to investigate the frequency-dependent spatiotemporal dynamics of spontaneous brain activity in ASD across three frequency bands: LFO (0.01-0.1 Hz), slow-5 (0.01-0.027 Hz), and slow-4 (0.027-0.073 Hz). Resting-state fMRI data were obtained from the NYU site of the ABIDE I database, comprising 52 individuals with ASD and 52 typical controls (TCs). Six CAPs were identified within each frequency band using k-means clustering. We then calculated and compared CAP dynamics, including the appearance frequency, duration, entry rate, and transition probability. Our results revealed that (1) CAPs across different frequency bands exhibited overall similar spatial patterns but showed significant differences in temporal evolution, with the slow-5 band demonstrating lower dynamic variability; (2) compared to the TC group, individuals with ASD exhibited abnormal brain dynamics in both the LFO and slow-4 bands, whereas no significant differences were observed in the slow-5 band; and (3) significant correlations were found between the dynamic metrics of CAPs in the LFO and slow-5 bands and the severity of restricted and repetitive behaviors (RRB) in individuals with ASD. These findings reveal frequency-specific abnormalities in brain dynamics in ASD, providing new insights into its time-varying neural mechanisms.

自闭症谱系障碍(ASD)是一种复杂的神经发育障碍,影响正常的大脑发育并导致大脑功能受损。大多数研究都集中在传统低频范围内的连接变化上,而大脑动力学的频率依赖性本质仍未得到很大程度的探索。本研究采用全脑共激活模式(CAP)分析ASD患者自发性脑活动在LFO (0.01 ~ 0.1 Hz)、slow-5 (0.01 ~ 0.027 Hz)和slow-4 (0.027 ~ 0.073 Hz)三个频带上的频率依赖时空动态。静息状态fMRI数据来自NYU网站的ABIDE I数据库,包括52名ASD患者和52名典型对照(tc)。使用k-means聚类在每个频带内识别出6个cap。然后我们计算并比较CAP动态,包括出现频率、持续时间、进入率和转移概率。结果表明:(1)不同频带的cap在空间格局上总体相似,但在时间演化上存在显著差异,其中慢5频带动态变异性较低;(2)与TC组相比,ASD个体在低动区和慢动区均表现出异常,而在慢动区无显著差异;(3) LFO和slow-5波段cap动态指标与ASD个体限制性重复行为(RRB)严重程度存在显著相关。这些发现揭示了自闭症患者大脑动力学中的频率特异性异常,为其时变神经机制提供了新的见解。
{"title":"Frequency-dependent brain state dynamic alterations in autism spectrum disorder: A co-activation pattern analysis.","authors":"Simeng An, Liming Fan, Yutong Wu, Xing Su, Qian Zhu, Nan Yao, Chunwang Su, Zi-Gang Huang, Youjun Li","doi":"10.1016/j.jpsychires.2026.02.006","DOIUrl":"https://doi.org/10.1016/j.jpsychires.2026.02.006","url":null,"abstract":"<p><p>Autism spectrum disorder (ASD) is a complex neurodevelopmental disorder that affects normal brain development and results in impaired brain function. Most studies have focused on connectivity changes within the traditional low-frequency range, whereas the frequency-dependent nature of brain dynamics remains largely unexplored. This study employed whole-brain co-activation pattern (CAP) analysis to investigate the frequency-dependent spatiotemporal dynamics of spontaneous brain activity in ASD across three frequency bands: LFO (0.01-0.1 Hz), slow-5 (0.01-0.027 Hz), and slow-4 (0.027-0.073 Hz). Resting-state fMRI data were obtained from the NYU site of the ABIDE I database, comprising 52 individuals with ASD and 52 typical controls (TCs). Six CAPs were identified within each frequency band using k-means clustering. We then calculated and compared CAP dynamics, including the appearance frequency, duration, entry rate, and transition probability. Our results revealed that (1) CAPs across different frequency bands exhibited overall similar spatial patterns but showed significant differences in temporal evolution, with the slow-5 band demonstrating lower dynamic variability; (2) compared to the TC group, individuals with ASD exhibited abnormal brain dynamics in both the LFO and slow-4 bands, whereas no significant differences were observed in the slow-5 band; and (3) significant correlations were found between the dynamic metrics of CAPs in the LFO and slow-5 bands and the severity of restricted and repetitive behaviors (RRB) in individuals with ASD. These findings reveal frequency-specific abnormalities in brain dynamics in ASD, providing new insights into its time-varying neural mechanisms.</p>","PeriodicalId":16868,"journal":{"name":"Journal of psychiatric research","volume":"196 ","pages":"234-243"},"PeriodicalIF":3.2,"publicationDate":"2026-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146226421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Oxytocin, social cognition, and neurocognitive function in male patients with schizophrenia: A prospective study 男性精神分裂症患者的催产素、社会认知和神经认知功能:一项前瞻性研究
IF 3.2 2区 医学 Q1 PSYCHIATRY Pub Date : 2026-02-10 DOI: 10.1016/j.jpsychires.2026.02.013
Şeyma Işık Karakulak , Süheyla Doğan Bulut , Hasan Karadağ , Zeynep Adıyaman Koçer

Objective

This study examined serum oxytocin levels during an acute psychotic episode and following antipsychotic treatment response in male patients with schizophrenia, and explored associations with social cognition and functional cognitive domains.

Method

The sample consisted of 51 male patients meeting DSM-5 criteria for schizophrenia who were assessed during an acute psychotic episode, and 41 healthy male controls. Sociodemographic characteristics, clinical symptoms, and functional status were evaluated using the Sociodemographic and clinical data form(SDVF), Positive and Negative Syndrome Scale (PANSS), Global Assessment of Functioning (GAF), Cognitive Assessment Interview–Turkish Version (CAI-TR), and Reading the Mind in the Eyes Test (RMET). Serum oxytocin levels were measured using enzyme-linked immunosorbent assay (ELISA). Patients who met the predefined treatment response criterion (≥25% reduction in PANSS total score, N = 33) underwent a second evaluation after a mean follow-up period of 12 weeks.

Results

Mean serum oxytocin levels were significantly lower in the patient group (143.94 ± 104.88 pg/mL) than in the control group (254.12 ± 152.58 pg/mL) (t68.28 = 3.93, p < 0.001, d = 0.86). Among the 33 treatment responders, oxytocin levels increased significantly from the acute episode to follow-up (152.55 ± 108.75 to 214.15 ± 115.79 pg/mL; t = 3.27, p = 0.003, d = 0.57). Baseline oxytocin levels were negatively correlated with PANSS Positive and General Psychopathology scores, and positively correlated with RMET and GAF scores. Increases in oxytocin levels following treatment occurred in parallel with improvements, particularly in social cognitive functioning.

Conclusion

These findings indicate that oxytocin levels in patients with schizophrenia are associated with social cognitive functioning and increase in parallel with improvements following treatment. Peripheral oxytocin levels may represent a promising candidate biomarker in schizophrenia.
目的研究男性精神分裂症患者急性精神病发作和抗精神病药物治疗后血清催产素水平,并探讨其与社会认知和功能认知领域的关系。方法51例符合DSM-5精神分裂症诊断标准的男性患者在急性精神病发作期间接受评估,41例健康男性作为对照。采用社会人口学和临床数据表(SDVF)、阳性和阴性综合征量表(PANSS)、整体功能评估(GAF)、认知评估访谈-土耳其版(CAI-TR)和眼读心术测试(RMET)对社会人口学特征、临床症状和功能状态进行评估。采用酶联免疫吸附试验(ELISA)测定血清催产素水平。满足预定治疗反应标准(PANSS总分降低≥25%,N = 33)的患者在平均随访12周后进行第二次评估。结果患者组平均血清催产素水平(143.94±104.88 pg/mL)显著低于对照组(254.12±152.58 pg/mL) (t68.28 = 3.93, p < 0.001, d = 0.86)。在33例治疗应答者中,从急性发作到随访,催产素水平显著升高(152.55±108.75 ~ 214.15±115.79 pg/mL; t = 3.27, p = 0.003, d = 0.57)。基线催产素水平与PANSS阳性和一般精神病理学评分呈负相关,与RMET和GAF评分呈正相关。治疗后催产素水平的增加与改善同时发生,特别是在社会认知功能方面。结论精神分裂症患者的催产素水平与社会认知功能相关,且治疗后催产素水平随治疗后社会认知功能的改善而升高。外周催产素水平可能是一种有希望的精神分裂症候选生物标志物。
{"title":"Oxytocin, social cognition, and neurocognitive function in male patients with schizophrenia: A prospective study","authors":"Şeyma Işık Karakulak ,&nbsp;Süheyla Doğan Bulut ,&nbsp;Hasan Karadağ ,&nbsp;Zeynep Adıyaman Koçer","doi":"10.1016/j.jpsychires.2026.02.013","DOIUrl":"10.1016/j.jpsychires.2026.02.013","url":null,"abstract":"<div><h3>Objective</h3><div>This study examined serum oxytocin levels during an acute psychotic episode and following antipsychotic treatment response in male patients with schizophrenia, and explored associations with social cognition and functional cognitive domains.</div></div><div><h3>Method</h3><div>The sample consisted of 51 male patients meeting DSM-5 criteria for schizophrenia who were assessed during an acute psychotic episode, and 41 healthy male controls. Sociodemographic characteristics, clinical symptoms, and functional status were evaluated using the Sociodemographic and clinical data form(SDVF), Positive and Negative Syndrome Scale (PANSS), Global Assessment of Functioning (GAF), Cognitive Assessment Interview–Turkish Version (CAI-TR), and Reading the Mind in the Eyes Test (RMET). Serum oxytocin levels were measured using enzyme-linked immunosorbent assay (ELISA). Patients who met the predefined treatment response criterion (≥25% reduction in PANSS total score, N = 33) underwent a second evaluation after a mean follow-up period of 12 weeks.</div></div><div><h3>Results</h3><div>Mean serum oxytocin levels were significantly lower in the patient group (143.94 ± 104.88 pg/mL) than in the control group (254.12 ± 152.58 pg/mL) (t<sub>68</sub>.<sub>28</sub> = 3.93, p &lt; 0.001, d = 0.86). Among the 33 treatment responders, oxytocin levels increased significantly from the acute episode to follow-up (152.55 ± 108.75 to 214.15 ± 115.79 pg/mL; t = 3.27, p = 0.003, d = 0.57). Baseline oxytocin levels were negatively correlated with PANSS Positive and General Psychopathology scores, and positively correlated with RMET and GAF scores. Increases in oxytocin levels following treatment occurred in parallel with improvements, particularly in social cognitive functioning.</div></div><div><h3>Conclusion</h3><div>These findings indicate that oxytocin levels in patients with schizophrenia are associated with social cognitive functioning and increase in parallel with improvements following treatment. Peripheral oxytocin levels may represent a promising candidate biomarker in schizophrenia.</div></div>","PeriodicalId":16868,"journal":{"name":"Journal of psychiatric research","volume":"196 ","pages":"Pages 124-131"},"PeriodicalIF":3.2,"publicationDate":"2026-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146172319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association between C-reactive protein and depression among alcohol users in the United States: A population-based analysis of National Health and Nutrition Examination Survey (NHANES) 2015-2020 美国酒精使用者中c反应蛋白与抑郁症之间的关系:2015-2020年国家健康与营养检查调查(NHANES)的基于人群的分析
IF 3.2 2区 医学 Q1 PSYCHIATRY Pub Date : 2026-02-10 DOI: 10.1016/j.jpsychires.2026.02.009
Lekshmi Rita-Venugopal , Tom Varghese M , Madhav KC

Background

Inflammation and alcohol use are linked to depression, but whether their effects are independent or interactive remains unclear.

Objective

To examine inflammation as an independent correlate of depression among U.S. adults who consume alcohol and a modifier of the alcohol–depression association.

Methods

Cross-sectional analysis of NHANES 2015–2020 including adults aged ≥18 reporting past-year alcohol use(n = 3019). Depression was assessed using the PHQ-9, with scores categorized as no depression(0), minimal(1–4), mild(5–9), and moderate–severe(10–27). Inflammation was measured using high-sensitivity CRP, categorized as low(≤1 mg/L), average(1–3 mg/L), and high(>3 mg/L). Alcohol use was classified as light, moderate, or heavy based on drinks/week and binge frequency. Modified Poisson regression with robust variance estimated prevalence ratios for depressive symptoms across CRP levels, adjusting for covariates (alcohol severity, age, sex, race/ethnicity, income, BMI, smoking, physical activity, sleep, comorbidities, drug use). Survey-weighted GLM models tested CRP–alcohol interactions.

Results

High CRP was associated with 13% higher mild and 22% higher moderate–severe depression prevalence (p < 0.0001) vs. low CRP. CRP–alcohol interactions were statistically significant with high CRP associated with increased depression prevalence among light drinkers (PR = 1.06,95% CI:1.05–1.07) and moderate drinkers (PR = 1.03,95% CI:1.01–1.04). Among heavy drinkers, high CRP showed an 8.2% increase, not statistically significant, likely due to limited power and dilution by acute inflammation. Sensitivity analyses excluding CRP >10 mg/L showed stronger effects (6–11% increase); high CRP × heavy drinking became significant (PR = 1.11,95% CI:1.05–1.18, p < 0.0001).

Conclusion

CRP was associated with higher depression and modified alcohol–depression associations. Inflammation amplified depression risk across drinking levels.
炎症和饮酒与抑郁症有关,但它们的影响是独立的还是相互作用的尚不清楚。目的研究炎症在美国成年人饮酒与抑郁之间的独立相关性,以及酒精与抑郁之间的关系。方法NHANES 2015-2020的横断面分析包括≥18岁报告过去一年饮酒的成年人(n = 3019)。抑郁症采用PHQ-9进行评估,得分分为无抑郁(0)、轻度抑郁(1-4)、轻度抑郁(5-9)和中度抑郁(10-27)。使用高敏CRP测量炎症,分为低(≤1mg /L)、平均(1 - 3mg /L)和高(3mg /L)。根据饮酒量/周和暴饮频率,将酒精使用分为轻度、中度和重度。校正协变量(酒精严重程度、年龄、性别、种族/民族、收入、体重指数、吸烟、体育锻炼、睡眠、合共病、药物使用)后,修正泊松稳健方差回归估计了CRP水平中抑郁症状的患病率。调查加权GLM模型测试了crp -酒精的相互作用。结果与低CRP相比,高CRP与轻度抑郁症患病率高13%和中重度抑郁症患病率高22%相关(p < 0.0001)。在轻度饮酒者(PR = 1.06,95% CI: 1.05-1.07)和中度饮酒者(PR = 1.03,95% CI: 1.01-1.04)中,CRP -酒精相互作用具有统计学意义,高CRP与抑郁症患病率增加相关。在重度饮酒者中,高CRP水平增加了8.2%,没有统计学意义,可能是由于急性炎症的作用有限和稀释。排除CRP + gt;10 mg/L的敏感性分析显示更强的影响(增加6-11%);高CRP与重度饮酒的关系变得显著(PR = 1.11,95% CI: 1.05-1.18, p < 0.0001)。结论crp与重度抑郁和改良的酒精性抑郁相关。炎症会在饮酒量上放大抑郁风险。
{"title":"Association between C-reactive protein and depression among alcohol users in the United States: A population-based analysis of National Health and Nutrition Examination Survey (NHANES) 2015-2020","authors":"Lekshmi Rita-Venugopal ,&nbsp;Tom Varghese M ,&nbsp;Madhav KC","doi":"10.1016/j.jpsychires.2026.02.009","DOIUrl":"10.1016/j.jpsychires.2026.02.009","url":null,"abstract":"<div><h3>Background</h3><div>Inflammation and alcohol use are linked to depression, but whether their effects are independent or interactive remains unclear.</div></div><div><h3>Objective</h3><div>To examine inflammation as an independent correlate of depression among U.S. adults who consume alcohol and a modifier of the alcohol–depression association.</div></div><div><h3>Methods</h3><div>Cross-sectional analysis of NHANES 2015–2020 including adults aged ≥18 reporting past-year alcohol use(n = 3019). Depression was assessed using the PHQ-9, with scores categorized as no depression(0), minimal(1–4), mild(5–9), and moderate–severe(10–27). Inflammation was measured using high-sensitivity CRP, categorized as low(≤1 mg/L), average(1–3 mg/L), and high(&gt;3 mg/L). Alcohol use was classified as light, moderate, or heavy based on drinks/week and binge frequency. Modified Poisson regression with robust variance estimated prevalence ratios for depressive symptoms across CRP levels, adjusting for covariates (alcohol severity, age, sex, race/ethnicity, income, BMI, smoking, physical activity, sleep, comorbidities, drug use). Survey-weighted GLM models tested CRP–alcohol interactions.</div></div><div><h3>Results</h3><div>High CRP was associated with 13% higher mild and 22% higher moderate–severe depression prevalence (p &lt; 0.0001) vs. low CRP. CRP–alcohol interactions were statistically significant with high CRP associated with increased depression prevalence among light drinkers (PR = 1.06,95% CI:1.05–1.07) and moderate drinkers (PR = 1.03,95% CI:1.01–1.04). Among heavy drinkers, high CRP showed an 8.2% increase, not statistically significant, likely due to limited power and dilution by acute inflammation. Sensitivity analyses excluding CRP &gt;10 mg/L showed stronger effects (6–11% increase); high CRP × heavy drinking became significant (PR = 1.11,95% CI:1.05–1.18, p &lt; 0.0001).</div></div><div><h3>Conclusion</h3><div>CRP was associated with higher depression and modified alcohol–depression associations. Inflammation amplified depression risk across drinking levels.</div></div>","PeriodicalId":16868,"journal":{"name":"Journal of psychiatric research","volume":"196 ","pages":"Pages 61-70"},"PeriodicalIF":3.2,"publicationDate":"2026-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146172342","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A systematic review and meta-analysis of anxiety and depression in children and adolescents with inflammatory bowel disease: Prevalence and association 儿童和青少年炎症性肠病患者焦虑和抑郁的系统回顾和荟萃分析:患病率和相关性
IF 3.2 2区 医学 Q1 PSYCHIATRY Pub Date : 2026-02-09 DOI: 10.1016/j.jpsychires.2026.02.008
Tingting Xu , Yanhong Chen , Qiqi Shen , Sichao Dai , Haohao Yan , Jianjuan Ren

Background

Anxiety and depression are prevalent comorbidities in patients with inflammatory bowel disease (IBD). However, their prevalence and impact in children and adolescents with IBD remain poorly defined. This meta-analysis aimed (i) to estimate the prevalence of anxiety and depression in this population and (ii) to explore the association between these psychological issues and IBD.

Methods

A thorough search of Embase, Web of Science, and PubMed from inception through February 1, 2025, was conducted. Two authors independently extracted data and assessed study quality. Pooled prevalence estimates, odds ratios (ORs), and hazard ratios (HRs) were calculated using a random-effects model. Subgroup and sensitivity analyses were performed to examine sources of heterogeneity and assess result robustness.

Results

The meta-analysis included 48 studies with 189,032 children and adolescents with IBD. Pooled prevalence estimates were as follows: anxiety symptoms (12%; 95% confidence interval [CI]: 7%–17%; k [number of studies] = 14; n [number of subjects] = 1574); anxiety disorders (9%; 95% CI: 5%–14%; k = 6; n = 168,378); depressive symptoms (15%; 95% CI: 11%–19%; k = 35; n = 4426); and depressive disorder (8%; 95% CI: 5%–11%; k = 7; n = 168,475). Pooled HRs indicated a significantly higher risk of developing anxiety and depressive disorders in this population, with HRs of 1.95 and 1.65, respectively.

Conclusions

Children and adolescents with IBD face a substantial burden of anxiety and depression. Routine mental health screening is essential for early intervention and comprehensive management of these comorbidities.
背景:焦虑和抑郁是炎症性肠病(IBD)患者普遍存在的合并症。然而,它们在患有IBD的儿童和青少年中的患病率和影响仍然不清楚。本荟萃分析旨在(1)估计该人群中焦虑和抑郁的患病率,(2)探讨这些心理问题与IBD之间的关系。方法全面检索Embase、Web of Science和PubMed自成立以来至2025年2月1日的文献。两位作者独立提取数据并评估研究质量。使用随机效应模型计算合并患病率估计值、优势比(ORs)和风险比(hr)。进行亚组分析和敏感性分析以检查异质性来源并评估结果的稳健性。荟萃分析包括48项研究,涉及189032名患有IBD的儿童和青少年。合并患病率估计如下:焦虑症状(12%;95%置信区间[CI]: 7%-17%; k[研究数]= 14;n[受试者数]= 1574);焦虑症(9%;95%置信区间:5% - -14%;k = 6; n = 168378);抑郁症状(15%;95% CI: 11%-19%; k = 35; n = 4426);抑郁症(8%;95% CI: 5%-11%; k = 7; n = 168,475)。合并hr表明该人群发生焦虑和抑郁障碍的风险显著增加,hr分别为1.95和1.65。结论儿童和青少年IBD患者面临着沉重的焦虑和抑郁负担。常规心理健康筛查对于这些合并症的早期干预和综合管理至关重要。
{"title":"A systematic review and meta-analysis of anxiety and depression in children and adolescents with inflammatory bowel disease: Prevalence and association","authors":"Tingting Xu ,&nbsp;Yanhong Chen ,&nbsp;Qiqi Shen ,&nbsp;Sichao Dai ,&nbsp;Haohao Yan ,&nbsp;Jianjuan Ren","doi":"10.1016/j.jpsychires.2026.02.008","DOIUrl":"10.1016/j.jpsychires.2026.02.008","url":null,"abstract":"<div><h3>Background</h3><div>Anxiety and depression are prevalent comorbidities in patients with inflammatory bowel disease (IBD). However, their prevalence and impact in children and adolescents with IBD remain poorly defined. This meta-analysis aimed (i) to estimate the prevalence of anxiety and depression in this population and (ii) to explore the association between these psychological issues and IBD.</div></div><div><h3>Methods</h3><div>A thorough search of Embase, Web of Science, and PubMed from inception through February 1, 2025, was conducted. Two authors independently extracted data and assessed study quality. Pooled prevalence estimates, odds ratios (ORs), and hazard ratios (HRs) were calculated using a random-effects model. Subgroup and sensitivity analyses were performed to examine sources of heterogeneity and assess result robustness.</div></div><div><h3>Results</h3><div>The meta-analysis included 48 studies with 189,032 children and adolescents with IBD. Pooled prevalence estimates were as follows: anxiety symptoms (12%; 95% confidence interval [CI]: 7%–17%; k [number of studies] = 14; n [number of subjects] = 1574); anxiety disorders (9%; 95% CI: 5%–14%; k = 6; n = 168,378); depressive symptoms (15%; 95% CI: 11%–19%; k = 35; n = 4426); and depressive disorder (8%; 95% CI: 5%–11%; k = 7; n = 168,475). Pooled HRs indicated a significantly higher risk of developing anxiety and depressive disorders in this population, with HRs of 1.95 and 1.65, respectively.</div></div><div><h3>Conclusions</h3><div>Children and adolescents with IBD face a substantial burden of anxiety and depression. Routine mental health screening is essential for early intervention and comprehensive management of these comorbidities.</div></div>","PeriodicalId":16868,"journal":{"name":"Journal of psychiatric research","volume":"196 ","pages":"Pages 78-89"},"PeriodicalIF":3.2,"publicationDate":"2026-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146172344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Associations of common antipsychotic medications with weight gain in youth and adults: a target trial emulation study 青少年和成人常用抗精神病药物与体重增加的关系:一项目标试验模拟研究
IF 3.2 2区 医学 Q1 PSYCHIATRY Pub Date : 2026-02-09 DOI: 10.1016/j.jpsychires.2026.02.007
Joshua Petimar , Sheryl L. Rifas-Shiman , Jessica G. Young , Han Yu , Matthew F. Daley , William J. Heerman , David M. Janicke , W. Schuyler Jones , Kristina H. Lewis , Pi-I.D. Lin , Doug Lunsford , L. Charles Bailey , Sengwee Toh , Jason P. Block

Background

Few real-world studies have estimated differences in weight gain between antipsychotic medications. This study estimated effects of initiating 4 first-line antipsychotic medications on weight change in adults and children/adolescents.

Methods

Electronic health record data were collected from 31,270 adults (≥20 years) and 29,496 children/adolescents (<20 years) newly prescribed 1 of 4 antipsychotics (aripiprazole, olanzapine, quetiapine, risperidone) from 2010 to 2019 across 15 U.S. health systems. Target trial emulation estimated the effect of initiating each medication on weight change in adults and body mass index z-score (BMIz) in children/adolescents at 6 (primary) and 12 months (secondary) versus aripiprazole (reference). Inverse probability weighted estimation of repeated outcome marginal structural models adjusted for baseline confounding and informative outcome measurement.

Results

In adults, initiation of aripiprazole was associated with greater 6-month weight change than initiation of olanzapine (difference = −0.60 kg [95% CI: −0.97, −0.25]), quetiapine (difference = −1.17 kg [-1.43, −0.91]), and risperidone (difference = −0.35 kg [-0.73, 0.03]); 12-month weight gain was similar between aripiprazole and olanzapine (difference = −0.11 [-0.61, 0.38]). In children/adolescents, olanzapine was associated with greater 6-month BMIz change than aripiprazole (difference = 0.15 [0.10, 0.20]); quetiapine and risperidone were associated with slightly smaller BMIz increases than aripiprazole. Six-month adherence was lower for olanzapine (5-7%) than other medications (15-21%) in adults and children/adolescents.

Conclusions

Among 4 first-line antipsychotic medications, aripiprazole was associated with the greatest 6-month weight gain in adults and olanzapine was associated with the greatest 6-month BMIz increase in children/adolescents, though adherence was lower for olanzapine than other medications. Clinicians should consider these differences in weight gain when initiating antipsychotic medications.
很少有真实世界的研究估计抗精神病药物在体重增加方面的差异。本研究估计了4种一线抗精神病药物对成人和儿童/青少年体重变化的影响。方法收集美国15个卫生系统2010年至2019年新开4种抗精神病药物(阿立哌唑、奥氮平、喹硫平、利培酮)中的1种的31,270名成人(≥20岁)和29,496名儿童/青少年(20岁)的电子健康记录数据。目标试验模拟评估了与阿立哌唑(参考)相比,开始使用每种药物对成人体重变化和儿童/青少年6个月(初级)和12个月(次级)体重指数z分数(BMIz)的影响。重复结果边际结构模型的逆概率加权估计,调整基线混淆和信息性结果测量。结果在成人中,与开始使用奥氮平(差异= - 0.60 kg [95% CI: - 0.97, - 0.25])、喹硫平(差异= - 1.17 kg[-1.43, - 0.91])和利培酮(差异= - 0.35 kg[-0.73, 0.03])相比,开始使用阿立哌唑的6个月体重变化更大;阿立哌唑和奥氮平12个月体重增加相似(差异= - 0.11[-0.61,0.38])。在儿童/青少年中,奥氮平与阿立哌唑的6个月bmi变化相关(差异= 0.15 [0.10,0.20]);与阿立哌唑相比,喹硫平和利培酮的BMIz升高幅度略小。在成人和儿童/青少年中,奥氮平的6个月依从性(5-7%)低于其他药物(15-21%)。结论在4种一线抗精神病药物中,阿立哌唑与成人6个月体重增加最多相关,奥氮平与儿童/青少年6个月体重增加最多相关,但奥氮平的依从性低于其他药物。临床医生在开始使用抗精神病药物时应考虑这些体重增加的差异。
{"title":"Associations of common antipsychotic medications with weight gain in youth and adults: a target trial emulation study","authors":"Joshua Petimar ,&nbsp;Sheryl L. Rifas-Shiman ,&nbsp;Jessica G. Young ,&nbsp;Han Yu ,&nbsp;Matthew F. Daley ,&nbsp;William J. Heerman ,&nbsp;David M. Janicke ,&nbsp;W. Schuyler Jones ,&nbsp;Kristina H. Lewis ,&nbsp;Pi-I.D. Lin ,&nbsp;Doug Lunsford ,&nbsp;L. Charles Bailey ,&nbsp;Sengwee Toh ,&nbsp;Jason P. Block","doi":"10.1016/j.jpsychires.2026.02.007","DOIUrl":"10.1016/j.jpsychires.2026.02.007","url":null,"abstract":"<div><h3>Background</h3><div>Few real-world studies have estimated differences in weight gain between antipsychotic medications. This study estimated effects of initiating 4 first-line antipsychotic medications on weight change in adults and children/adolescents.</div></div><div><h3>Methods</h3><div>Electronic health record data were collected from 31,270 adults (≥20 years) and 29,496 children/adolescents (&lt;20 years) newly prescribed 1 of 4 antipsychotics (aripiprazole, olanzapine, quetiapine, risperidone) from 2010 to 2019 across 15 U.S. health systems. Target trial emulation estimated the effect of initiating each medication on weight change in adults and body mass index z-score (BMIz) in children/adolescents at 6 (primary) and 12 months (secondary) versus aripiprazole (reference). Inverse probability weighted estimation of repeated outcome marginal structural models adjusted for baseline confounding and informative outcome measurement.</div></div><div><h3>Results</h3><div>In adults, initiation of aripiprazole was associated with greater 6-month weight change than initiation of olanzapine (difference = −0.60 kg [95% CI: −0.97, −0.25]), quetiapine (difference = −1.17 kg [-1.43, −0.91]), and risperidone (difference = −0.35 kg [-0.73, 0.03]); 12-month weight gain was similar between aripiprazole and olanzapine (difference = −0.11 [-0.61, 0.38]). In children/adolescents, olanzapine was associated with greater 6-month BMIz change than aripiprazole (difference = 0.15 [0.10, 0.20]); quetiapine and risperidone were associated with slightly smaller BMIz increases than aripiprazole. Six-month adherence was lower for olanzapine (5-7%) than other medications (15-21%) in adults and children/adolescents.</div></div><div><h3>Conclusions</h3><div>Among 4 first-line antipsychotic medications, aripiprazole was associated with the greatest 6-month weight gain in adults and olanzapine was associated with the greatest 6-month BMIz increase in children/adolescents, though adherence was lower for olanzapine than other medications. Clinicians should consider these differences in weight gain when initiating antipsychotic medications.</div></div>","PeriodicalId":16868,"journal":{"name":"Journal of psychiatric research","volume":"196 ","pages":"Pages 90-96"},"PeriodicalIF":3.2,"publicationDate":"2026-02-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146172345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reply to "Letter to the Editor: Temporal patterns of suicide following psychiatric discharge". 回复“致编辑的信:精神病出院后自杀的时间模式”。
IF 3.2 2区 医学 Q1 PSYCHIATRY Pub Date : 2026-02-05 DOI: 10.1016/j.jpsychires.2026.02.002
Kristoffer Bele Ødegård, Martin Øverlien Myhre, Ole Klungsøyr, Lars Mehlum, Anita Johanna Tørmoen, Fredrik A Walby
{"title":"Reply to \"Letter to the Editor: Temporal patterns of suicide following psychiatric discharge\".","authors":"Kristoffer Bele Ødegård, Martin Øverlien Myhre, Ole Klungsøyr, Lars Mehlum, Anita Johanna Tørmoen, Fredrik A Walby","doi":"10.1016/j.jpsychires.2026.02.002","DOIUrl":"https://doi.org/10.1016/j.jpsychires.2026.02.002","url":null,"abstract":"","PeriodicalId":16868,"journal":{"name":"Journal of psychiatric research","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146142804","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Circulating levels of glial cell line-derived neurotrophic factor in bipolar disorder: A meta-analysis of case-control studies and efficacy of therapeutic interventions 双相情感障碍患者神经胶质细胞系源性神经营养因子的循环水平:病例对照研究和治疗干预效果的荟萃分析。
IF 3.2 2区 医学 Q1 PSYCHIATRY Pub Date : 2026-02-05 DOI: 10.1016/j.jpsychires.2026.02.005
Omran Davarinejad , Saeid Komasi , Mohammad-Taher Moradi , Fatemeh Kazemisafa

Background

Bipolar disorder (BD) is a chronic and debilitating mental illness characterized by alternating episodes of mania and depression, affecting approximately 5-6% of the global population. Despite extensive research, the underlying pathophysiology of BD remains poorly understood, necessitating further exploration of potential biomarkers. This meta-analysis investigates peripheral levels of glial cell line-derived neurotrophic factor (GDNF) to evaluate its utility as a biomarker in individuals with BD.

Methods

We systematically searched four international databases, identifying 13 case-control studies (825 patients with BD vs. 885 healthy controls) and 4 clinical trials encompassing 153 patients with BD. The study adhered to PRISMA guidelines and employed rigorous quality assessment tools, including the Newcastle-Ottawa Scale for observational studies and the Cochrane Risk of Bias tool for clinical trials.

Results

The analysis revealed a pooled standardized mean difference of d = −0.81 [CI: 1.41 to −0.22], p = 0.007. However, extreme heterogeneity (I2 > 96%) and publication bias preclude reliable interpretation of this estimate. Furthermore, the meta-regression analyses were significant for illness duration, YMRS score, and year of study. Subgroup analysis showed significant estimates for blood sample, mania episode, and Asian region. Although treatment interventions increased GDNF levels, these changes were not statistically significant (d = 0.12, [95% CI: 0.20 to 0.44], p = 0.463). High heterogeneity was observed across studies, indicating substantial variability in study designs and participant characteristics.

Conclusion

The literature provides preliminary, highly heterogeneous evidence suggestive of altered GDNF levels in BD, primarily within serum during mania. The plasma-serum discrepancy highlights a major methodological confounder (platelet GDNF release), and the significant heterogeneity and publication bias preclude a reliable estimate of the true effect size. GDNF cannot be considered a disorder-specific biomarker for BD, as similar alterations are reported in major depression and schizophrenia. Future research must prioritize plasma measurements, standardized protocols, and longitudinal designs in medication-naïve cohorts to clarify whether GDNF acts as a state-dependent marker of acute mood episodes within a transdiagnostic framework.
背景:双相情感障碍(BD)是一种以躁狂症和抑郁症交替发作为特征的慢性衰弱性精神疾病,影响全球约5-6%的人口。尽管进行了广泛的研究,但双相障碍的潜在病理生理机制仍然知之甚少,需要进一步探索潜在的生物标志物。这项荟萃分析研究了神经胶质细胞系来源的神经营养因子(GDNF)的外周水平,以评估其作为bd患者生物标志物的效用。我们系统地检索了4个国际数据库,确定了13项病例对照研究(825名双相障碍患者与885名健康对照)和4项临床试验,包括153名双相障碍患者。该研究遵循PRISMA指南,并采用严格的质量评估工具,包括观察性研究的纽卡斯尔-渥太华量表和临床试验的Cochrane偏倚风险工具。结果:分析显示合并标准化平均差d = -0.81 [CI: 1.41 ~ -0.22], p = 0.007。然而,极端的异质性(96%)和发表偏倚妨碍了对这一估计的可靠解释。此外,meta回归分析在疾病持续时间、YMRS评分和学习年份方面具有显著性。亚组分析显示血液样本、躁狂发作和亚洲地区有显著的估计。虽然治疗干预增加了GDNF水平,但这些变化没有统计学意义(d = 0.12, [95% CI: 0.20 ~ 0.44], p = 0.463)。在研究中观察到高度异质性,表明研究设计和参与者特征存在很大差异。结论:文献提供了初步的、高度异质性的证据,表明双相障碍患者的GDNF水平发生了改变,主要是在躁狂期间的血清中。血浆-血清差异突出了一个主要的方法学混杂因素(血小板GDNF释放),并且显著的异质性和发表偏倚排除了对真实效应大小的可靠估计。GDNF不能被认为是双相障碍的疾病特异性生物标志物,因为在重度抑郁症和精神分裂症中也有类似的改变。未来的研究必须优先考虑血浆测量、标准化方案和medication-naïve队列的纵向设计,以澄清GDNF是否在跨诊断框架内作为急性情绪发作的状态依赖标志物。
{"title":"Circulating levels of glial cell line-derived neurotrophic factor in bipolar disorder: A meta-analysis of case-control studies and efficacy of therapeutic interventions","authors":"Omran Davarinejad ,&nbsp;Saeid Komasi ,&nbsp;Mohammad-Taher Moradi ,&nbsp;Fatemeh Kazemisafa","doi":"10.1016/j.jpsychires.2026.02.005","DOIUrl":"10.1016/j.jpsychires.2026.02.005","url":null,"abstract":"<div><h3>Background</h3><div>Bipolar disorder (BD) is a chronic and debilitating mental illness characterized by alternating episodes of mania and depression, affecting approximately 5-6% of the global population. Despite extensive research, the underlying pathophysiology of BD remains poorly understood, necessitating further exploration of potential biomarkers. This meta-analysis investigates peripheral levels of glial cell line-derived neurotrophic factor (GDNF) to evaluate its utility as a biomarker in individuals with BD.</div></div><div><h3>Methods</h3><div>We systematically searched four international databases, identifying 13 case-control studies (825 patients with BD vs. 885 healthy controls) and 4 clinical trials encompassing 153 patients with BD. The study adhered to PRISMA guidelines and employed rigorous quality assessment tools, including the Newcastle-Ottawa Scale for observational studies and the Cochrane Risk of Bias tool for clinical trials.</div></div><div><h3>Results</h3><div>The analysis revealed a pooled standardized mean difference of d = −0.81 [CI: 1.41 to −0.22], p = 0.007. However, extreme heterogeneity (I<sup>2</sup> &gt; 96%) and publication bias preclude reliable interpretation of this estimate. Furthermore, the meta-regression analyses were significant for illness duration, YMRS score, and year of study. Subgroup analysis showed significant estimates for blood sample, mania episode, and Asian region. Although treatment interventions increased GDNF levels, these changes were not statistically significant (<em>d</em> = 0.12, [95% CI: 0.20 to 0.44], <em>p</em> = 0.463). High heterogeneity was observed across studies, indicating substantial variability in study designs and participant characteristics.</div></div><div><h3>Conclusion</h3><div>The literature provides preliminary, highly heterogeneous evidence suggestive of altered GDNF levels in BD, primarily within serum during mania. The plasma-serum discrepancy highlights a major methodological confounder (platelet GDNF release), and the significant heterogeneity and publication bias preclude a reliable estimate of the true effect size. GDNF cannot be considered a disorder-specific biomarker for BD, as similar alterations are reported in major depression and schizophrenia. Future research must prioritize plasma measurements, standardized protocols, and longitudinal designs in medication-naïve cohorts to clarify whether GDNF acts as a state-dependent marker of acute mood episodes within a transdiagnostic framework.</div></div>","PeriodicalId":16868,"journal":{"name":"Journal of psychiatric research","volume":"196 ","pages":"Pages 30-39"},"PeriodicalIF":3.2,"publicationDate":"2026-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146137573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of psychiatric research
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1